Johns Hopkins gets FDA approval to test blood plasma therapy to treat COVID-19 patients

14:58, 07.04.2020

The U.S. Food and Drug Administration approved a clinical trial Friday that will allow Johns Hopkins University researchers to test a therapy for COVID-19 that uses plasma from recovering patients.

Arturo Casadevall, a Johns Hopkins infectious disease expert, proposed the use of convalescent plasma to treat critically ill COVID-19 patients and to boost the immune systems of health care providers and first responders.
He assembled a team of physicians and scientists from around the United States to establish a network of hospitals and blood banks that can collect, isolate, and process blood plasma from COVID-19 survivors.

“The ability to carry out a prophylaxis trial will tell us whether plasma is effective in protecting our health care workers and first responders from COVID-19,” said Casadevall, a Bloomberg Distinguished Professor who holds joint appointments in the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins School of Medicine.

Medicine

World

COVID-19

Johns Hopkins University

plasma